Recombinant Human Low affinity immunoglobulin epsilon Fc receptor (FCER2)

What is FCER2 and what is its primary function in human immunology?

FCER2, also known as CD23, functions as the low-affinity Fc receptor for IgE. When expressed on B cells, it plays a critical role in regulating IgE synthesis through a negative feedback mechanism . The protein is a type II integral membrane protein with a single transmembrane region, where the carboxy-terminal region is extracellular and the amino-terminal domain is intracytoplasmic . FCER2 has several additional designations including BLAST-2, C-type lectin domain family 4 member J, Fc-epsilon-RII, and Immunoglobulin E-binding factor .

Methodologically, researchers investigating FCER2 function typically employ:

• Flow cytometry to assess expression levels on immune cells

• Binding assays to measure IgE-FCER2 interactions

• Gene expression analysis to quantify FCER2 regulation

• Cell culture systems with B cell transfectants to study functional properties

How does FCER2 structurally interact with IgE molecules?

FCER2 interacts with IgE through its extracellular domain. Research has demonstrated that certain genetic variants of FCER2, such as the R62W polymorphism (rs2228137), can significantly alter IgE binding affinity. Experimental evidence shows that B cells expressing the CD23b-R62W variant bind IgE with greater affinity than wild-type cells . The binding affinity (Ka) values were calculated to be significantly higher for the variant form compared to wild-type .

For researchers investigating this interaction:

• Surface plasmon resonance provides quantitative binding kinetics

• Competitive binding assays can determine relative affinities

• Structural biology approaches (X-ray crystallography, cryo-EM) reveal molecular interfaces

• Site-directed mutagenesis helps identify critical binding residues

Which FCER2 polymorphisms are most strongly associated with asthma, and what are their functional consequences?

Multiple polymorphisms in the FCER2 gene have been associated with asthma susceptibility and phenotypes. The most extensively studied include:

The rs2228137 polymorphism (R62W) is located in exon 4 of the FCER2 gene in the extracellular segment of the protein close to the transmembrane domain . This variation appears to confer significant functional changes, as B-cell transfectants expressing the R62W SNP show increased IL-4R expression after CD23 stimulation, which may facilitate signaling through IL-4 and favor class switching to increase IgE synthesis .

Research methodologies for investigating these associations include:

• Case-control genetic association studies

• Functional assays with cell lines expressing variant forms

• Haplotype analysis to identify combinatorial genetic effects

• Expression quantitative trait loci (eQTL) analysis

How do FCER2 polymorphisms influence response to asthma treatments?

FCER2 polymorphisms have been linked to differential responses to asthma treatments, particularly inhaled corticosteroids. Research has identified that certain FCER2 variants are associated with an increased risk of exacerbations in asthmatic children taking inhaled corticosteroids, despite the generally protective effects of this medication class .

In a significant study, children homozygous for a specific FCER2 variant showed substantially increased risk of exacerbations: hazard ratios were 3.95 (95% CI: 1.64–9.51) for Caucasian children and 3.08 (95% CI: 1.00–9.47) for African–American children . This variant was also associated with both differences in IgE levels and differential expression of the FCER2 gene, supporting the hypothesis that variation in FCER2 can adversely affect normal negative feedback mechanisms in IgE regulation .

Researchers investigating pharmacogenetic relationships should consider:

• Prospective clinical trials stratified by FCER2 genotype

• Biomarker studies correlating genotype with treatment response

• In vitro assays examining corticosteroid response pathways in cells with different FCER2 variants

• Systems biology approaches to understand pathway interactions

What expression systems are optimal for producing recombinant FCER2 for research purposes?

Production of recombinant FCER2 has been successfully accomplished using several expression systems, each with distinct advantages for different research applications:

Commercial recombinant human FCER2 is available as a partial protein (expression region 48-248aa) with an N-terminal 6xHis-tag, commonly expressed in E. coli with a theoretical molecular weight of 27.3 kDa . For functional studies, researchers often develop stable human B-cell transfectants expressing wild-type or variant FCER2 .

Methodological considerations include:

• Codon optimization for the chosen expression system

• Inclusion of appropriate purification tags

• Validation of proper folding and activity

• Storage conditions to maintain stability

What techniques provide the most reliable assessment of FCER2 binding kinetics?

Several techniques yield quantitative insights into FCER2-IgE binding kinetics, each offering different advantages:

• Surface Plasmon Resonance (SPR):

  • Provides real-time, label-free measurements

  • Determines association (kon) and dissociation (koff) rate constants

  • Calculates equilibrium dissociation constant (KD)

  • Requires relatively pure protein samples

• Bio-Layer Interferometry (BLI):

  • Similar advantages to SPR but with different optical detection

  • More tolerant of crude samples

  • Easier to implement in high-throughput format

• Isothermal Titration Calorimetry (ITC):

  • Measures thermodynamic parameters (ΔH, ΔS)

  • Does not require immobilization or labeling

  • Provides stoichiometry information

• Flow Cytometry-Based Binding Assays:

  • Assesses binding on cell surface-expressed FCER2

  • Can be used with intact cells

  • Provides information about binding in a more physiological context

Research has employed these techniques to demonstrate that CD23b-R62W-expressing human B cells bind IgE with greater affinity than wild-type cells .

What evidence supports the role of FCER2 as a common genetic link between asthma and COPD?

Research increasingly supports the Dutch hypothesis proposing that asthma and COPD may share common genetic origins. FCER2 has emerged as one of the genes potentially linking these conditions:

• Genetic association studies have identified FCER2 polymorphisms associated with both diseases:

  • The rs28364072 SNP shows significant differences between COPD patients and controls (P=0.009)

  • The rs2228137 variant is associated with asthma susceptibility (P=0.010)

• Functional impacts relevant to both conditions:

  • FCER2 haplotypes were associated with pulmonary function measurements in both asthma and COPD patients

  • FCER2 variants correlate with blood eosinophil counts in both diseases

• Potential therapeutic implications:

  • These findings suggest that anti-IgE biologics, currently used in asthma treatment, might benefit specific COPD subtypes

Research methodologies to investigate this connection include:

• Comparative genetic studies in asthma and COPD cohorts

• Functional characterization of shared genetic variants

• Development of animal models expressing disease-associated variants

• Transcriptomic and proteomic analyses of airway samples

How do FCER2 polymorphisms contribute to eosinophilic inflammation in respiratory diseases?

FCER2 polymorphisms appear to influence eosinophilic inflammation through several mechanisms:

• Altered IgE regulation:

  • Certain FCER2 variants result in increased IgE binding affinity

  • This may disrupt the normal negative feedback control of IgE production

  • Elevated IgE levels can promote eosinophil recruitment and activation

• Direct effects on inflammatory signaling:

  • FCER2 variants show differences in ERK1/2 activation kinetics

  • This alters downstream signaling cascades involved in inflammatory responses

  • Changes in Egr-1 mRNA levels have been observed after stimulation through variant CD23

• Clinical correlations:

  • FCER2 haplotypes are associated with blood eosinophil counts in both asthma and COPD patients

  • These associations suggest a mechanistic link between genetic variation and cellular phenotype

Researchers investigating these relationships typically employ:

• Flow cytometric assessment of eosinophil counts and activation markers

• Cytokine profiling of patient samples

• In vitro cell culture models with variant FCER2 expression

• Transgenic animal models to study pathway effects in vivo

What are the methodological challenges in targeting FCER2 for therapeutic development?

Developing therapeutics targeting FCER2 presents several methodological challenges:

• Structural complexity:

  • FCER2 exists in both membrane-bound and soluble forms

  • The protein undergoes post-translational modifications affecting function

  • Targeting specific domains without disrupting beneficial functions requires precision

• Functional redundancy:

  • The immune system has multiple regulatory pathways for IgE

  • Complete inhibition may have unintended consequences for immune defense

  • Partial modulation may be insufficient for clinical benefit

• Genetic heterogeneity:

  • Population variation in FCER2 polymorphisms affects treatment response

  • Personalized approaches may be needed based on genetic profiles

  • Clinical trials must account for genetic stratification

• Technical challenges:

  • Developing high-specificity binding molecules

  • Ensuring adequate drug delivery to relevant tissues

  • Monitoring target engagement in vivo

Future research approaches should consider:

• Structure-based drug design targeting specific FCER2 domains

• Development of allele-specific therapeutics for variant forms

• Combination approaches targeting multiple points in the IgE regulatory pathway

• Biomarker strategies to identify patients most likely to benefit

How can systems biology approaches enhance our understanding of FCER2 in immune network regulation?

Systems biology offers powerful frameworks to understand FCER2's role within broader immune regulatory networks:

• Multi-omics integration:

  • Combining genomic, transcriptomic, and proteomic data

  • Correlating FCER2 genetic variants with expression changes and protein interaction networks

  • Identifying key nodes and feedback loops in IgE regulation

• Network modeling:

  • Constructing mathematical models of FCER2 signaling pathways

  • Simulating the effects of genetic variants on pathway dynamics

  • Predicting emergent behaviors in complex immune networks

• Single-cell approaches:

  • Characterizing cell-specific FCER2 expression patterns

  • Identifying rare cell populations with unique FCER2 functions

  • Mapping cellular communication networks involving FCER2

• Translational integration:

  • Correlating molecular findings with clinical phenotypes

  • Developing predictive models for treatment response

  • Designing rational combination therapies based on network analysis

These approaches collectively enable:

• Identification of novel therapeutic targets connected to FCER2 pathways

• Better prediction of treatment responses based on network states

• More comprehensive understanding of how FCER2 variants affect global immune regulation

• Integration of FCER2 research with broader immunological mechanisms